Frontlight ResearchEarly access
CompletedPhase 3
Long-term Safety of TPN171H Tablet in Erectile Dysfunction.
Key facts
- Who runs it
- Vigonvita Life Sciences
- Where
- China34 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 472 people enrolled
- Started
- 12 Apr 2024
- Ended
- 5 Jun 2025
- Type of study
- Interventional
- Treatments tested
- TPN171H
- Record updated
- 25 July 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- 18 years to 75 years (inclusive)
- Males with ED at least 3 months
- IIEF-5 ≤ 21 at visit 1
- Patients in a stable, heterosexual relationship during the study
- At the end of the untreated baseline period, the following conditions are met:(1)The subject must make at least four attempts at sexual intercourse during the untreated baseline period. (2)At least 50% of attempts during this period must be unsuccessful,(unsuccess means at least one of the first three questions should be answered "No" in SEP).(3)5≤IIEF-EF≤25
- Patients who are willing to have 4 or more attempts of sexual intercourse per month, demonstrated compliance with the study protocol, including drug administration, diary completion, and scheduled study visits, during the qualifying trial
- Patients who are willing to take proper contraceptive during the study and within 3 months after the last dose
- Patients who have voluntarily decided to participate in this study, and signed the informed consent form
Who cannot take part
- Patients with ED, which is caused by spinal injury or have had a radical prostatectomy or other surgery
- Patients who have a penile implant
- Patients who do not respond to marketed PDE5 inhibitors or have adverse reactions that lead to drug discontinuation
- CYP3A4 potent inhibitors, moderate inhibitors, and potent inducers need to be used during the trial or discontinued for less than 31 days before enrollment
- Subjects who are taking nitrate or NO donor drugs, guanylate cyclase agonists and cannot be discontinued during the trial
- Patients who have used other drugs in clinical trials within the last 1 month
- Patients who have a history of hypersensitivity to other PDE5 inhibitors or TPN171H
- Patients with ED, which is caused by any other primary sexual disorder
- Patients with the following cardiovascular disease: Myocardial infarction or stroke within the last 6 months; Unstable angina or angina occurring during sexual intercourse; New York Heart Association Class 2 or greater heart failure in the last 6 months
- Uncontrolled hypotension (<90/60mmHg) or uncontrolled hypertension (≥180/110mmHg)
- Patients with active gastrointestinal ulcers and bleeding disorders
- Patients who have a history of NAION, or with a known genetically degenerative retinopathy, including retinitis pigmentosa
- Patients who have a history of sudden decrease or loss of hearing
- Patients with a history of severe central nervous system injury or peripheral muscular neurological disease in the past 6 months
- Patient with a history of malignancy
- Patients whose partner is breastfeeding/pregnant/trying to become pregnant, has a gynecological disease or is restricted in their activities during treatment
- Patients with hepatic or renal dysfunction as per the following: AST, ALT>3*ULN, serum creatinine exceeds 50% of the upper limit of normal value
- Patients with anatomical malformations of the penis
- Patients with primary hypoactive sexual desire
- Patients with diabetic complications (diabetic nephropathy, peripheral neuropathy)
- Patients with significant neurological abnormalities who are unable or unwilling to cooperate
- For other reasons besides the aforementioned cases, patient whose participation is deemed inappropriate
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, open study to evaluate the long-term safety and efficacy of TPN171H in men with erectile dysfunction.
The group in the trial
- TPN171H groupTreatment being tested
10 mg/ time, as needed, it is recommended to take warm water within 0.5 to 4 hours before sexual activity.
Treatment: TPN171H
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Open Study to Evaluate the Long-term Safety and Efficacy of TPN171H in Patients With Erectile Dysfunction
- Record updated
- 25 July 2025